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OBJECTIVE — The severity of peripheral neuropathy in diabetic patients varies for unclear
reasons.Long-termuseofmetforminisassociatedwithmalabsorptionofvitaminB12(cobalamin
[Cbl])andelevatedhomocysteine(Hcy)andmethylmalonicacid(MMA)levels,whichmayhave
deleterious effects on peripheral nerves. The intent of this study was to clarify the relationship
amongmetforminexposure,levelsofCbl,Hcy,andMMA,andseverityofperipheralneuropathy
in diabetic patients. We hypothesized that metformin exposure would be associated with lower
Cbl levels, elevated Hcy and MMA levels, and more severe peripheral neuropathy.
RESEARCH DESIGN AND METHODS — This was a prospective case-control study of
patients with type 2 diabetes and concurrent symptomatic peripheral neuropathy, comparing
those who had received 6 months of metformin therapy (n  59) with those without met-
formin exposure (n  63). Comparisons were made using clinical (Toronto Clinical Scoring
System and Neuropathy Impairment Score), laboratory (serum Cbl, fasting Hcy, and fasting
MMA), and electrophysiological measures (nerve conduction studies).
RESULTS — Metformin-treated patients had depressed Cbl levels and elevated fasting MMA
and Hcy levels. Clinical and electrophysiological measures identiﬁed more severe peripheral
neuropathy in these patients; the cumulative metformin dose correlated strongly with these
clinical and paraclinical group differences.
CONCLUSIONS — Metformin exposure may be an iatrogenic cause for exacerbation of
peripheral neuropathy in patients with type 2 diabetes. Interval screening for Cbl deﬁciency and
systemic Cbl therapy should be considered upon initiation of, as well as during, metformin
therapy to detect potential secondary causes of worsening peripheral neuropathy.
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D
iabetes is an increasingly prevalent
disorder with a range of systemic
complications including diabetic
peripheral neuropathy (DPN), which oc-
curs in up to 50% of diabetic patients and
causes sensory, motor, and/or autonomic
dysfunction (1). Several pathogenic
mechanisms contribute to DPN severity,
including microangiopathy, oxidative
stress, polyol ﬂux, mitochondrial dys-
function, insulin deﬁciency, and ad-
vancedglycationendproductsandligand
activation of their receptor (2–5). The
course and severity of DPN are further
affected by a wide range of comorbid
conditions.
Vitamin B12 (cobalamin [Cbl]) deﬁ-
ciency may co-occur with diabetes. Al-
though it is most classically associated
withsubacutecombineddegeneration,an
exclusive peripheral neuropathy presen-
tation can occur, typically manifesting as
axonal neuropathy based on electrophys-
iology and pathology (6–8). Accumulat-
ing evidence suggests that Cbl-associated
metabolites methylmalonic acid (MMA)
and homocysteine (Hcy) are more sensi-
tive (MMA and Hcy) and speciﬁc (MMA)
indicators of early symptomatic Cbl deﬁ-
ciency than serum Cbl itself (9,10).
Metformin, a biguanide, is perenni-
ally reported as a pharmacological cause
of Cbl deﬁciency (11–13). The responsi-
ble mechanism has been controversial;
proposed contributors have included
competitive inhibition or inactivation of
Cbl absorption, alterations in intrinsic
factor levels, bacterial ﬂora, gastrointesti-
nal motility, or ileal morphological struc-
ture, and interaction with the cubulin
endocytic receptor (11,14,15). Bigua-
nides have recently been shown to impair
calcium-dependent membrane activity in
the ileum, including uptake of the Cbl-
intrinsic factor complex (16).
Metformin is recommended by the
American Diabetes Association and the
European Association for the Study of Di-
abetesasinitialmedicaltherapyfortype2
diabetes at diagnosis (17). Despite its
wide use and its known effects on Cbl,
metformin has not been systematically
studied as a potential iatrogenic cause of
orcontributortoDPN.Thepotentiallyre-
versible effect of cobalamin deﬁciency
may increase the clinical burden for a
population of patients with DPN whose
sensory function, gait, and balance fre-
quently are already compromised.
We designed a prospective case-
control study to assess the effects of pro-
longed metformin intake in patients with
type 2 diabetes matched for disease dura-
tion and disease control. We speciﬁcally
examined the relationship among met-
formin use, levels of Cbl and its metabo-
lites,andclinicalandelectrophysiological
markers of peripheral neuropathy sever-
ity. We hypothesized ﬁrst that metformin
usewouldbeassociatedwithbiochemical
evidence of Cbl deﬁciency (lower serum
Cbl levels and elevated MMA and Hcy)
and second that metformin use would be
associated with more severe peripheral
neuropathy. Decreases in Cbl have been
shown to depend on the dose and dura-
tion of metformin therapy in a previous
case-control study (18); this ﬁnding led
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cal abnormalities and severity of neurop-
athy would correlate with cumulative
lifetime metformin dose.
RESEARCH DESIGN AND
METHODS— Ethical approval for
this study was received from the Univer-
sityofCalgaryCentreforAdvancementof
Health. From December 2002 until May
2007, patients with preexisting type 2 di-
abetes and a primary diagnosis of periph-
eral neuropathy were assessed within the
NeuromuscularClinicattheUniversityof
Calgary. These patients then underwent
further clinical, laboratory, and electro-
physiological evaluation of their neurop-
athy. The presence of diabetes was
veriﬁed by two separate positive results:
two prior fasting glucose results of 7.1
mmol/l (126 mg/dl) or two oral glucose
tolerance tests leading to a 2-h serum glu-
coseof11.1mmol/l(200mg/dl)(based
on Canadian Diabetes Association guide-
lines). The age of diagnosis of diabetes
and the duration of symptoms of DPN
were recorded. History of other systemic
illnesses, alcohol use, toxin and medica-
tionexposures,andfamilyhistoryofneu-
ropathy was documented to assess for
other potential causes of peripheral neu-
ropathy. The duration of metformin ther-
apy and dosage history were determined
foreachpatientbyreviewoftheirmedical
record,andthesedosageswereconﬁrmed
verbally by the patients; these data were
used to calculate a cumulative lifetime
doseofmetforminforeachpatient.Useof
other antidiabetic agents was recorded.
All patients underwent laboratory
testingincludingacompletebloodcount,
electrolytes,urea,creatinine,alanineami-
notransferase, aspartate aminotransfer-
ase, -glutamyltranspeptidase, alkaline
phosphatase, albumin, total bilirubin, in-
ternational normalized ratio, thyroid-
stimulating hormone, erythrocyte
sedimentation rate, antinuclear antibody,
extracted nuclear antibody, serum pro-
tein electrophoresis, rheumatoid factor,
lactate, and serum folate. A1C was mea-
sured in all patients. The sensitivity for
detection of gammopathy in our center is
2 g/l by serum protein electrophoresis,
with immunoﬁxation performed when
peaks are found in the range of 2–4 g/l.
SerumCbllevelsweremeasuredbycobas
e immunoassay analysis (Roche Diagnos-
tics), Hcy levels were measured using
high-performance liquid chromatogra-
phy, and MMA levels were measured us-
ing mass spectrometry for all patients.
The lower limit of normal for Cbl in our
centeris210pmol/l(285pg/ml).Theup-
per limit for Hcy is 13.7 mol/l (1.85
mg/l) in adult men, 9.9 mol/l (1.34
mg/l)inadultwomenaged49yearsand
12.8 mol/l (1.73 mg/l) in adult women
aged 49 years; here we adopt a conser-
vative upper limit of 13.7 mol/l (1.85
mg/l) for all participants. The upper limit
of normal for MMA in our center is 0.15
mol/l. All blood testing was performed
by Calgary Laboratory Services.
Patients were excluded if potential
causes for peripheral neuropathy other
than diabetes and Cbl deﬁciency were
identiﬁed, if they had previously been
treated with metformin and had discon-
tinued therapy, if they had received 6
months of metformin treatment at the
time of assessment, if they had impaired
glucose tolerance only, or if they had ju-
venileonsetofdiabetesorafrankrequire-
mentforinsulinatdiagnosis(i.e.,possible
type 1 diabetes). Last, patients were ex-
cluded if they refused concurrent electro-
physiological or laboratory testing. We
didnotexcludepatientswithrenalfailure
concurrently using metformin, although
renal failure is often considered a contra-
indication to metformin use because of
the potential for lactic acidosis; however,
many patients do not discontinue met-
forminuseafterdiagnosisofrenalimpair-
ment (19), and lactate levels were normal
in all patients.
Complete standardized neurological
examinations were performed in all pa-
tients with DPN, including tone, power,
deep tendon reﬂexes, sensory function,
Romberg testing, gait, and tandem gait.
Tandem gait was recorded as the number
ofheeltotoestepsalongastraightlinethe
patientcouldperformtoanormalthresh-
old value of 6. Each patient was also
scored using the Toronto Clinical Scoring
System (TCSS) (20) by an unblinded in-
vestigator before knowledge of laboratory
results.TheTCSSwasdevelopedasaclin-
ical screening tool for the presence and
severity of DPN that emphasizes sensory
deﬁcits.Althoughitintroducessomesub-
jectivity in scoring, it has been validated
by sural nerve ﬁber density. We also de-
termined the Neuropathy Impairment
Score (NIS), a scale scoring weakness of
groups of muscles of the head and neck,
upper limbs, and lower limbs; tactile, vi-
bratory,andjointpositionsensation;pin-
prick sensation of index ﬁngers and great
toes; and reﬂexes, for each patient (21).
Electrophysiological assessment was
performed after clinical assessment and
before knowledge of the laboratory re-
sults using a Dantec Datapoint (Dantec
Dynamics, Bristol, U.K.). Sensory and
motor nerves of the nondominant upper
and lower extremities were tested within
3 months of clinical assessment. Motor
nerve conduction studies (NCSs) were
performed using stimulation of the me-
dian nerve (wrist and elbow), ulnar nerve
(wrist, below elbow, and above elbow),
peroneal nerve (ankle and below ﬁbular
head and above ﬁbular head locations),
and tibial nerve (ankle and popliteal fossa
locations). For each motor nerve, distal
motor latencies, compound motor action
potentials, and conduction velocities
wereobtainedorcalculated.Fwavelaten-
cies were obtained from median, ulnar,
peroneal,andtibialnerves.SensoryNCSs
were performed using the median (digits
2and4),ulnar(digits4and5),superﬁcial
radial, superﬁcial peroneal, and sural
nerves with sensory nerve action poten-
tials (SNAPs), onset latency, and conduc-
tion velocity obtained or calculated.
Temperatures were maintained at 32°C
for the upper extremities and 30°C for
the lower extremities during NCS testing.
Although all participants completed elec-
trophysiological testing, some partici-
pants do not have complete data for all
individual nerves.
Afterallclinical,electrophysiological,
and laboratory testing, monthly intra-
muscularCblwasprescribedforthosepa-
tients with abnormal Cbl, MMA, or Hcy
levels. Sural nerve biopsies were done
only in clinical situations when vasculitis
or another serious cause of peripheral
neuropathy was suspected.
Group equivalence for patient age,
duration of type 2 diabetes, duration of
peripheral neuropathy symptoms, A1C,
and alcohol exposure were compared by
independent-samples t tests; sex and pro-
portion using other antidiabetic agents
werecomparedby
2test.Elementsofthe
past medical history (e.g., iron deﬁciency
anemia and hereditary spherocytosis)
were broadly classiﬁed (e.g., hematologi-
cal disease) and are summarized in Table
1; these were not compared statistically
because of their heterogeneity. These ele-
ments of the history are detailed in the
appendix (available online at http://care.
diabetesjournals.org/cgi/content/full/dc09-
0606/DC1). The primary outcome measures
were Hcy, MMA, and Cbl blood levels,
clinical neuropathy severity (TCSS and
NIS), and electrophysiological markers of
neuropathy; of the latter, we chose to test
sensory NCS in the lower extremity (con-
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peroneal and sural nerves), as we felt
these would be most in keeping with ex-
acerbation due to Cbl deﬁciency. These
data did not follow a normal distribution
(by Shapiro-Wilk test), and comparisons
were made using a Mann-Whitney U test.
Proportions of patients with deﬁciency of
Cbl and upregulation of Hcy and MMA
were compared using 
2 tests. Bivariate
correlations of clinical and laboratory
variables with cumulative metformin dose
were calculated using a Spearman  test.
Last, a linear regression analysis was per-
formed using the NIS total score as the
dependent variable and age, duration of
diabetes,A1C,andpresenceofmetformin
exposure as explanatory variables.
RESULTS— Of226patientswithtype
2 diabetes and peripheral neuropathy as-
sessed for eligibility, 104 patients were
excluded; 55 had brief (6 months) met-
formin exposure, 46 patients discontin-
ued metformin before assessment, and 3
were unable to perform laboratory or
electrophysiological testing. Of the 122
patients who were eligible for analysis, 59
(48%)receivedmetformintherapyfor6
months (mean cumulative exposure
3,389.5 g, 2,560.6 g); the remaining
patients had no prior metformin expo-
sure. There were no signiﬁcant differ-
ences in demographic variables (age and
sex)ordiseaseseverity(durationoftype2
diabetes, A1C, and duration of peripheral
neuropathy symptoms) between the two
groups (Table 1). A signiﬁcantly higher
number of patients in the metformin-
treated group were concurrently treated
with glyburide and signiﬁcantly fewer
with insulin (Table 1). There were no
other notable differences in prescription
medication use, presence of other sys-
temic conditions, or alcohol exposure
among groups (Table 1; details are avail-
able in the online appendix).
Analysis of laboratory testing is sum-
marized in Table 2. Median serum Cbl
was signiﬁcantly lower in the metformin-
treated group (231 vs. 486 pmol/l; U 
299.0, P  0.001) with frank deﬁciency
in 18 patients (31%) compared with 2
(3%) in the non–metformin-treated
group (P  0.001). Cumulative met-
formindosewasinverselycorrelatedwith
serum Cbl (Spearman 	 0.41, two-
tailed P  0.001). Median fasting serum
Hcy was signiﬁcantly higher in the met-
formin-treated group (11.6 vs. 8.4
mol/l; U  454.0, P  0.001) with up-
regulation of Hcy in 15 patients versus 1
patient (P  0.001). Median MMA was
signiﬁcantly higher in the metformin-
treated group (0.18 vs. 0.11 mol/l; U 
306.5, P  0.001) and upregulated in 43
of these patients compared with 7 pa-
tients with no metformin exposure (P 
0.001). Cumulative metformin dose was
positively correlated with fasting serum
Hcy (Spearman 0.50, two-tailed P 
0.001) and fasting serum MMA (Spear-
man 0.37, two-tailed P  0.005)
(Fig. 1).
Clinical and paraclinical markers of
neuropathy severity are summarized in
Table2.ThemedianTCSStotalscorewas
higher in the metformin-treated group
(10 vs. 5; U  527.0, P  0.001), with a
strong positive correlation to increasing
cumulative metformin dose (Spearman
0.80, two-tailed P  0.001). Median
NIS total score was signiﬁcantly higher in
the metformin-treated group (10 vs. 4;
U  408.0, P  0.001) and also had a
strong positive correlation with increas-
ing cumulative metformin dose (Spear-
man0.79,two-tailedP0.001)(Fig.
1). Left sural (metformin-treated n  41;
non–metformin-treated n  51) and su-
perﬁcial peroneal nerves (metformin-
treated n  39; non–metformin-treated
n  49) had lower median SNAP and
slower median conduction velocity in the
metformin-treated group; however, these
measures were not signiﬁcantly different
between groups after corrections for mul-
tiple comparisons (Table 2).
Inthelinearregressionanalysis,using
the enter method, a signiﬁcant model
emerged (F4, 117  47.7, P  0.005) with
adjusted R
2  0.61. Metformin exposure
(
0.55, P  0.001) and duration of
diabetes (
0.41, P  0.001) were the
only signiﬁcant explanatory variables in
this model. Collinearity diagnostics did
not suggest a problem with multicol-
linearity in this model (variance inﬂation
factor 1.5 for all included variables).
CONCLUSIONS — We found evi-
dence that patients with type 2 diabetes,
peripheral neuropathy, and 6 months’
exposure to metformin had lower serum
Cbl, higher serum Hcy and MMA, and
higher scores on the NIS and TCSS, indi-
cating clinically more severe peripheral
neuropathy compared with similar pa-
tientswithnometforminexposure.These
abnormalities were correlated strongly
with cumulative metformin exposure. A
linear regression analysis including age,
Table 1—Patient characteristics
Metformin-
treated
Non–metformin-
treated P
n 59 63
Demographic variables
Age (years) 66.6  11.9 64.8  12.0 NS*
Female sex (%) 24 (41) 29 (46) NS
Disease severity
Duration of diabetes (years) 5.5  3.3 4.7  2.9 NS
Duration of peripheral neuropathy
symptoms (years) 3.8  2.1 3.8  2.4 NS
A1C (%) 6.7  1.0 6.8  1.1 NS
Other diabetes pharmacotherapy
Glyburide use 38 (64) 22 (35) 0.001†
Gliclazide use 18 (31) 15 (24) NS
Insulin therapy 7 (12) 29 (46) 0.001†
Clinical history
Alcohol exposure (drinks/week) 3.0  4.5 2.2  4.0 NS
History of ﬁrst-degree relatives with
peripheral neuropathy 4 (5) 0
Rheumatological disease (osteoarthritis
or rheumatoid arthritis) 7 (12) 4 (6)
Elevated creatinine with renal failure 6 (10) 7 (11)
Thyroid disease 11 (19) 16 (25)
Hematologic disease 5 (8) 0
Cancer 7 (12) 7 (11)
Other illness 42 (71) 29 (46)
Data are means  SD or n (%). *NS at the 0.05 level. †Signiﬁcant at 0.05 level for 
2 test.
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exposuretopredictclinicalstatus(NISto-
tal score) showed that metformin expo-
sure and duration of diabetes were
signiﬁcant explanatory variables. We
were unable to demonstrate signiﬁcant
group differences in sural or superﬁcial
peroneal SNAP or conduction velocity.
Metformin-associated Cbl deﬁciency
may contribute to the clinical burden of
DPN; this contribution is both detectable
andameliorable.Thisdeﬁciencyandcon-
comitantincreaseinserumHcyhavebeen
demonstratedinarandomizedcontrolled
trial (22), and this relationship depends
Figure 1—Correlational analysis. Correla-
tion of lifetime cumulative metformin dose
with serum Cbl (A), fasting Hcy (B), MMA
(C),TCSStotalscore(D),andNIStotalscore
(E).Eachpointrepresentsanindividual.Cor-
relationcoefﬁcients(Spearman)wereasfol-
lows: Cbl 	0.41, P  0.001; Hcy 0.50, P 
0.001; MMA 0.37, P  0.005; TCSS total
score 0.80, P  0.001; and NIS total score
0.79, P  0.001. Dashed lines indicate the
lower limit of normal (Cbl) and upper limits
of normal (Hcy and MMA) for our center.
Table 2—Markers of Cbl deﬁciency and neuropathy severity
Metformin-treated Non–metformin-treated P
Correlation with cumulative
metformin dose P
n 59 63
Biochemical markers of Cbl deﬁciency
Serum Cbl (pmol/l) 231 (343) 486 (863) 0.001* 	0.41 0.001†
Cbl deﬁciency (210 pmol/l) 18 (31%) 2 (3%) 0.001*
Fasting serum Hcy (mol/l) 11.6 (17.7) 8.4 (24.9) 0.001* 0.50 0.001†
Hcy upregulation (13.7 mol/l) 15 (25%) 1 (2%) 0.001*
Fasting serum MMA (mol/l) 0.18 (0.47) 0.11 (0.14) 0.001* 0.37 0.005†
MMA upregulation (0.15 mol/l) 43 (73%) 7 (11%) 0.001*
Clinical markers of neuropathy severity
TCSS total score 10 (17) 5 (12) 0.001* 0.80 0.001†
NIS total score 10 (32) 4 (12) 0.001* 0.79 0.001†
Electrophysiological markers of
neuropathy severity
Left sural nerve SNAP amplitude (V) 3.0 (11.4) 4.4 (12.9) 0.038
Left sural nerve sensory conduction
velocity (m/s) 33.3 (15.0) 33.0 (15.7) 0.69
Left superﬁcial peroneal nerve SNAP
amplitude (V) 2.5 (7.1) 3.6 (7.8) 0.12
Left superﬁcial peroneal nerve sensory
conduction velocity (m/s) 34.2 (18.4) 36.8 (18.8) 0.071
Data are median (range) or n (%). *Signiﬁcant at Bonferroni corrected 0.05 level using Mann-Whitney U testing. †Two-tailed correlation coefﬁcient signiﬁcant
at Bonferroni corrected 0.05 level using Spearman  testing.
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apy (18). However, the potential for clin-
ical sequelae has been discussed only
rarely (11,16) and has not previously
been studied formally. The present ﬁnd-
ings therefore add clinical relevance to
the existing literature on metformin-
associated Cbl deﬁciency. Given the
prevalence of type 2 diabetes and of met-
formin use, these effects have the poten-
tial to be widespread.
The present ﬁndings should not be
seen to discourage treatment of diabetic
patients with neurological impairment
with metformin; in addition to its effects
onmetaboliccontrol,metforminhasbeen
shown to have beneﬁcial effects on ad-
vanced glycation end product formation
inperipheralnerves(23)andmayprevent
apoptosis involved in diabetes-associated
neurodegenerative processes (24). In-
stead, we recommend screening for fea-
turesofCbldeﬁciencyindiabeticpatients
receiving long-term metformin therapy.
The American Academy of Neurology
recommends serum Cbl and metabolites
(MMA with or without Hcy) as investiga-
tions with a high diagnostic yield in distal
symmetric polyneuropathy (10); this
yield may be further increased in the
present population given their predilec-
tionforcomorbidCbldeﬁciency.Theop-
timal screening frequency remains to be
determined,butbaselinetestsatinitiation
of metformin therapy and at intervals of
no more than 1–2 years seem prudent,
because metformin may begin to depress
serum Cbl levels after as short a time as 3
months (15).
It is unclear whether Cbl supplemen-
tation will prevent clinical worsening in
this group, but supplementation carries a
low risk of toxicity. Current therapy con-
sists of intramuscular Cbl replacement
therapy and possible long-term Cbl and
folate therapy; oral Cbl supplementation
may be as effective as intramuscular ther-
apy, although long-term outcomes have
not yet been examined in patients with
DPN (25). Oral calcium supplementation
has also been effective in reversing bio-
available Cbl deﬁciency in metformin-
treated patients (16).
Further studies should better deﬁne
differences in the electrophysiological
proﬁle of these groups. Potential central
nervous system complications of Cbl de-
ﬁciency, including myelopathy and cog-
nitive impairment, should be considered
as contributors to clinical status. The re-
lationshipamongCbldeﬁciency,elevated
HcyandMMAlevels,andperipheralneu-
ropathyiscontroversialandremainstobe
proven, but both Cbl deﬁciency and ele-
vation of its serum metabolites are associ-
ated with the presence of a sensorimotor
peripheral neuropathy (7).
Ourﬁndingsarepresentedwithsome
limitations. Although we identiﬁed pa-
tients prospectively, they were not ran-
domly selected from a population with
type2diabeteswithorwithoutDPN.Our
sample size was not based on a predeter-
mined power analysis. We did not iden-
tify a separate group of patients with
asymptomatic DPN. We excluded pa-
tientswithtype1diabetesbecauseoftheir
expected limited metformin exposure
and the potential for distinct pathophysi-
ological mechanisms. Although A1C was
notsigniﬁcantlydifferentbetweengroups
at the time of evaluation, we did not ex-
aminemeasuresofmetaboliccontrolover
time. Investigators were blinded to the
laboratory results until clinical and elec-
trophysiological studies were completed
but were not blinded to use of metformin
therapy.
Metformin-treated patients were
more commonly treated with glyburide
and less commonly with insulin therapy;
insulin may be beneﬁcial in diabetic pa-
tients with peripheral neuropathy be-
cause of mechanisms other than glycemic
correction (3). Undetected group differ-
ences may also exist; additional factors
such as inadequate dietary intake might
explain in part the lower Cbl levels in our
metformin-exposed patients, and it is
possible that patients using metformin
may have more severe diabetes despite
thesimilardurationoftype2diabetesand
similarA1Clevelsamonggroups.Allpar-
ticipants had normal folate status, but
pyridoxine levels were not measured.
Laboratory testing for pernicious anemia
(by the Schilling test) was not available
during this investigation, and therefore
the prevalence of this alternate cause of
Cbl deﬁciency in our population is not
known. Our multiple regression analysis
should be interpreted with caution as not
all variables potentially relevant to the
NIStotalscoreweremeasuredinourpop-
ulation, and our participants were
grouped in a nonrandom manner.
The current ﬁndings suggest an as-
sociation among metformin, elevated
Cbl metabolites, and exacerbation of
DPN, but further work is needed to
proveadirectcausalrelationshipandits
mechanism. Metformin may exacerbate
peripheral neuropathy as a result of other
unknown mechanisms; a clear under-
standing of its role necessarily awaits fur-
therresearchonthepathogenesisofDPN.
Despite these limitations, we believe that
metformin exposure is a potential iatro-
genic contributor to the severity of pe-
ripheral neuropathy in the population
described. Recognition of this readily
identiﬁableandpotentiallytreatablecom-
ponent of disease might improve quality
of life for this large population of diabetic
patients.
Acknowledgments— C.T. receives funding
from the Alberta Heritage Medical Research
Foundation (research into diabetes compli-
cations of the nervous system). This agency
had no role in design, conduct of the study,
collection, management, analysis or inter-
pretation of the data, review, or manuscript
approval.
No potential conﬂicts of interest relevant to
this article were reported.
References
1. Boulton AJ, Vinik AI, Arezzo JC, Bril V,
FeldmanEL,FreemanR,MalikRA,Maser
RE, Sosenko JM, Ziegler D. Diabetic neu-
ropathies: a statement by the American
DiabetesAssociation.DiabetesCare2005;
28:956–962
2. Huang TJ, Price SA, Chilton L, Calcutt
NA, Tomlinson DR, Verkhratsky A,
Fernyhough P. Insulin prevents depolar-
ization of the mitochondrial inner mem-
brane in sensory neurons of type 1
diabetic rats in the presence of sustained
hyperglycemia. Diabetes 2003;52:2129–
2136
3. Toth C, Brussee V, Zochodne DW. Re-
mote neurotrophic support of epidermal
nerve ﬁbres in experimental diabetes.
Diabetologia 2006;49:1081–1088
4. Toth C, Rong LL, Yang C, Martinez J,
Song F, Ramji N, Brussee V, Liu W, Du-
rand J, Nguyen MD, Schmidt AM, Zo-
chodne DW. Receptor for advanced
glycation end products (RAGEs) and ex-
perimental diabetic neuropathy. Diabetes
2008;57:1002–1017
5. Zochodne DW. Diabetic polyneuropathy:
an update. Curr Opin Neurol 2008;21:
527–533
6. Healton EB, Savage DG, Brust JC, Garrett
TJ, Lindenbaum J. Neurologic aspects of
cobalamin deﬁciency. Medicine (Balti-
more) 1991;70:229–245
7. Saperstein DS, Wolfe GI, Gronseth GS,
Nations SP, Herbelin LL, Bryan WW,
Barohn RJ. Challenges in the identiﬁca-
tionofcobalamin-deﬁciencypolyneurop-
athy. Arch Neurol 2003;60:1296–1301
8. Fine EJ, Soria E, Paroski MW, Petryk D,
Thomasula L. The neurophysiological
proﬁle of vitamin B12 deﬁciency. Muscle
Nerve 1990;13:158–164
Metformin and diabetic peripheral neuropathy
160 DIABETES CARE, VOLUME 33, NUMBER 1, JANUARY 2010 care.diabetesjournals.org9. Kumar N. Nutritional neuropathies. Neu-
rol Clin 2007;25:209–255
10. England JD, Gronseth GS, Franklin G,
Carter GT, Kinsella LJ, Cohen JA, Asbury
AK, Szigeti K, Lupski JR, Latov N, Lewis
RA, Low PA, Fisher MA, Herrmann DN,
Howard JF Jr, Lauria G, Miller RG, Poly-
defkis M, Sumner AJ, American Academy
of Neurology. Practice Parameter: evalua-
tion of distal symmetric polyneuropathy:
role of laboratory and genetic testing (an
evidence-based review). Report of the
American Academy of Neurology, Amer-
ican Association of Neuromuscular and
Electrodiagnostic Medicine, and Amer-
ican Academy of Physical Medicine and
Rehabilitation. Neurology 2009;72:177–
184
11. Tomkin GH, Hadden DR, Weaver JA,
Montgomery DA. Vitamin-B12 status of
patientsonlong-termmetformintherapy.
BMJ 1971;2:685–687
12. Gilligan MA. Metformin and vitamin B12
deﬁciency. Arch Intern Med 2002;162:
484–485
13. Liu KW, Dai LK, Jean W. Metformin-re-
lated vitamin B12 deﬁciency. Age Ageing
2006;35:200–201
14. Caspary WF, Zavada I, Reimold W, Deu-
tickeU,EmrichD,WillmsB.Alterationof
bile acid metabolism and vitamin-B12-
absorption in diabetics on biguanides.
Diabetologia 1977;13:187–193
15. Buvat DR. Use of metformin is a cause of
vitamin B12 deﬁciency. Am Fam Physi-
cian 2004;69:264
16. BaumanWA,ShawS,JayatillekeE,Spun-
gen AM, Herbert V. Increased intake of
calcium reverses vitamin B12 malabsorp-
tioninducedbymetformin.DiabetesCare
2000;23:1227–1231
17. NathanDM,BuseJB,DavidsonMB,Heine
RJ, Holman RR, Sherwin R, Zinman B.
Management of hyperglycemia in type 2
diabetes: a consensus algorithm for the
initiation and adjustment of therapy: a
consensus statement from the American
Diabetes Association and the European
Association for the Study of Diabetes.
Diabetes Care 2006;29:1963–1972
18. Ting RZ, Szeto CC, Chan MH, Ma KK,
Chow KM. Risk factors of vitamin B12 de-
ﬁciency in patients receiving metformin.
Arch Intern Med 2006;166:1975–1979
19. Emslie-Smith AM, Boyle DI, Evans JM,
Sullivan F, Morris AD, DARTS/MEMO
Collaboration. Contraindications to met-
formin therapy in patients with type 2 di-
abetes—a population-based study of
adherence to prescribing guidelines. Dia-
bet Med 2001;18:483–488
20. Bril V, Perkins BA. Validation of the To-
ronto Clinical Scoring System for diabetic
polyneuropathy. Diabetes Care 2002;25:
2048–2052
21. Dyck PJ, Litchy WJ, Lehman KA, Hokan-
son JL, Low PA, O’Brien PC. Variables in-
ﬂuencing neuropathic endpoints: the
Rochester Diabetic Neuropathy Study
of Healthy Subjects. Neurology 1995;45:
1115–1121
22. Wulffele ´ MG, Kooy A, Lehert P, Bets D,
Ogterop JC, Borger van der Burg B,
Donker AJ, Stehouwer CD. Effects of
short-term treatment with metformin on
serum concentrations of homocysteine
folate and vitamin B12 in type 2 diabetes
mellitus: a randomized placebo-con-
trolled trial. J Intern Med 2003;254:455–
463
23. TanakaY,UchinoH,ShimizuT,YoshiiH,
Niwa M, Ohmura C, Mitsuhashi N,
Onuma T, Kawamori R. Effect of met-
formin on advanced glycation endprod-
uct formation and peripheral nerve
functioninstreptozotocin-induceddiabetic
rats. Eur J Pharmacol 1999;376:17–22
24. El-Mir MY, Detaille D, R-Villanueva G,
Delgado-Esteban M, Guigas B, Attia S,
Fontaine E, Almeida A, Leverve X. Neu-
roprotectiveroleofantidiabeticdrugmet-
formin against apoptotic cell death in
primary cortical neurons. J Mol Neurosci
2008;34:77–87
25. ButlerCC,Vidal-AlaballJ,Cannings-John
R,McCaddonA,HoodK,PapaioannouA,
Mcdowell I, Goringe A. Oral vitamin B12
versus intramuscular vitamin B12 for vi-
tamin B12 deﬁciency: a systematic review
of randomized controlled trials. Fam
Pract 2006;23:279–285
Wile and Toth
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 1, JANUARY 2010 161